ChiCTR2300070241 版本V1.1 版本创建时间2023/05/30 09:58:35 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300070241 

最近更新日期:

Date of Last Refreshed on:

2023-04-06 15:15:19 

注册时间:

Date of Registration:

2023-04-06 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于真实世界中西医结合防治子痫前期临床决策支持系统的实效研究与应用示范

Public title:

A real-world pragmatic research and application demonstration on the effectiveness of a combined traditional Chinese and Western medicine based clinical decision support system for the prevention and treatment of preeclampsia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于真实世界中西医结合防治子痫前期临床决策支持系统的实效研究与应用示范

Scientific title:

A real-world pragmatic research and application demonstration on the effectiveness of a combined traditional Chinese and Western medicine based clinical decision support system for the prevention and treatment of preeclampsia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

肖信 

研究负责人:

马银瑶 

Applicant:

xiaoxin 

Study leader:

mayinyao 

申请注册联系人电话:

Applicant telephone:

15878757511

研究负责人电话:

Study leader's
telephone:

18260890572

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

qyykyb@163.com

研究负责人电子邮件:

Study leader's E-mail:

26032182@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广西南宁市桃源路6号

研究负责人通讯地址:

广西南宁市桃源路6号

Applicant address:

No. 6 Taoyuan Road, Nanning City, Guangxi

Study leader's address:

No. 6 Taoyuan Road, Nanning City, Guangxi

申请注册联系人邮政编码:

Applicant postcode:

430021

研究负责人邮政编码:

Study leader's postcode:

430021

申请人所在单位:

广西壮族自治区人民医院

Applicant's institution:

THE PECPLE'S HOSPITAL OF GUANGXI DHUANG AUTONOMOUS REGION

研究负责人所在单位:

广西壮族自治区人民医院

Affiliation of the Leader:

THE PECPLE'S HOSPITAL OF GUANGXI DHUANG AUTONOMOUS REGION

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY-KJT-2021-67号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广西壮族自治区人民医院伦理委员会

Name of the ethic committee:

THE PECPLE'S HOSPITAL OF GUANGXI DHUANG AUTONOMOUS REGION ETHICS COMMITTEE

伦理委员会批准日期:

Date of approved by ethic committee:

2021-08-23 00:00:00

伦理委员会联系人:

邱想英

Contact Name of the ethic committee:

qiuxiangyin

伦理委员会联系地址:

广西南宁市桃源路6号

Contact Address of the ethic committee:

No. 6 Taoyuan Road, Nanning City, Guangxi

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 771 5722415

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广西壮族自治区人民医院

Primary sponsor:

THE PECPLE'S HOSPITAL OF GUANGXI DHUANG AUTONOMOUS REGION

研究实施负责(组长)单位地址:

广西南宁市桃源路6号

Primary sponsor's address:

No. 6 Taoyuan Road, Nanning City, Guangxi

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广西壮族自治区

市(区县):

Country:

china

Province:

GUANGXI DHUANG AUTONOMOUS REGION

City:

单位(医院):

广西壮族自治区人民医院

具体地址:

广西南宁市桃源路6号

Institution
hospital:

THE PECPLE'S HOSPITAL OF GUANGXI DHUANG AUTONOMOUS REGION

Address:

No. 6 Taoyuan Road, Nanning City, Guangxi

经费或物资来源:

财政资金

Source(s) of funding:

Financial resources

研究疾病:

子痫前期  

Target disease:

Preeclampsia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

对子痫前期临床辅助决策支持系统在真实世界的有效性和安全性进行验证  

Objectives of Study:

Verify the effectiveness and safety of the preeclampsia clinical assisted decision support system in the real world data

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1、在广西壮族自治区人民医院进行规律孕检; 2、年龄18周岁及以上 3、入组时间为孕16周之前 4、未见孕期严重并发症

Inclusion criteria

1. Carry out regular pregnancy tests in the People's Hospital of Guangxi Zhuang Autonomous Region; 2. Age 18 and above 3. Enrollment time is before 16 weeks of pregnancy 4. No serious complications during pregnancy

排除标准:

1、依从性较差,不愿接受孕检所必须的各项检查。 2、排除有阿司匹林过敏史的孕产妇。

Exclusion criteria:

1. Poor compliance, unwilling to accept all examinations necessary for pregnancy examination. 2. Pregnant women with a history of aspirin allergy were excluded.

研究实施时间:

Study execute time:

From 2022-04-01 00:00:00 To 2025-03-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-04-29 00:00:00 To 2025-03-03 00:00:00

干预措施:

Interventions:

组别:

辅助决策支持系统组

样本量:

500

Group:

CDSS group

Sample size:

干预措施:

辅助决策支持系统指导基础治疗

干预措施代码:

Intervention:

CDSS guides basic therapy

Intervention code:

组别:

对照组

样本量:

500

Group:

control group

Sample size:

干预措施:

按照临床常规诊疗进行

干预措施代码:

Intervention:

According to clinical routine diagnosis and treatment

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广西壮族自治区 

市(区县):

 

Country:

china

Province:

GUANGXI DHUANG AUTONOMOUS REGION

City:

单位(医院):

广西壮族自治区人民医院 

单位级别:

三级甲等 

Institution
hospital:

THE PECPLE'S HOSPITAL OF GUANGXI DHUANG AUTONOMOUS REGION

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

子痫前期发病率

指标类型:

主要指标

Outcome:

Incidence rate of preeclampsia

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

子痫前期相关并发症

指标类型:

次要指标

Outcome:

Preeclampsia related complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

子痫前期发病孕周

指标类型:

次要指标

Outcome:

Preeclampsia onset gestational week

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

子痫前期发病严重程度

指标类型:

次要指标

Outcome:

Severity of preeclampsia onset

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

信息化平台随机算法

Randomization Procedure (please state who generates the random number sequence and by what method):

Random algorithm of information platform

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

本研究不设置盲法

Blinding:

No blind method is set in this study

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

如对原始数据有合理需求者,可通过与项目负责人电子邮件联系获取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The raw data can be accessed via e-mail with PI, if reasonable request is met.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic data capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-04-06 15:15:01